Three years after its initial FDA approval, Roche has made up for an early disadvantage with its blood cancer drug Lunsumio ...

Roche’s executives at JP Morgan 2025 spoke candidly about the company’s need to be more deliberate in its approach on how ...

Deals between pharmaceutical companies and Washington to reduce prices for medicines in the United States will likely push up ...

The White House is set to announce drug pricing deals with pharmaceutical heavyweights Novartis AG and Roche Holding AG as ...

The results of the lidERA trial in patients with HR-positive, HER2-negative early breast cancer – previewed last month and ...

Roche has secured CE Mark approval for its cobas BV/CV assay to support the diagnosis of infectious causes of vaginitis.

Giredestrant lowered the risk of disease recurrence or death by 30%, compared with standard-of-care endocrine therapy, ...

Roche’s data on Wednesday come from the Phase III lidERA Breast Cancer study, which assessed the adjuvant use of giredestrant ...

Roche (RHHBY) (RHHBF) on Wednesday announced additional data from a Phase 3 trial for its selective estrogen receptor ...

Caris Life Sciences, Inc. is rated a Hold with positive EBITDA & free cash flow driven by strong MI segment performance. Read ...

Roche's giredestrant cut recurrence risk by 30% in the phase 3 lidERA study, showing strong benefits in early ER-positive ...